Overview

The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod will be administered orally to pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.

Principal investigator

Eligibility criteria

Inclusion Criteria:
*  Moderately to severely active Ulcerative Colitis (UC) diagnosed prior to the Screening Visit
*  Evidence of UC extending beyond the rectum, as determined by baseline endoscopy
*  Has had an inadequate response, loss of response to, or is intolerant to at least 1 of the following treatments for UC: oral aminosalicylates, systemic corticosteroids, immunomodulators, biologic therapy

Exclusion Criteria:
*  Diagnosis of Crohn's disease or indeterminate colitis
*  Has documentation of positive test for toxin producing Clostridium difficile, or polymerase chain reaction examination of the stool
*  Apheresis within 2 weeks of randomization
*  History of or currently active primary or secondary immunodeficiency, or participants with known genetic disorders as a cause for colitis Other protocol-defined inclusion/exclusion criteria apply
Show more

Participate in this trial

Are you interested in enrolling in this study? Learn more here.

I'm Interested In Participating

For Referring Providers

Do you have a patient you think would be a good candidate for this trial? Learn more about enrolling your patient.

Contact the study coordinator

Dawn Ebach
Enroll your patient